Watch SLS. Know when insiders buy.
One email the day a filing lands. Free.
SLS
SELLAS Life Sciences Group, Inc.
12.14
+0.16 +1.34%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · shorts 43
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.5BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$32.5MNET CASH $138.2M52W 1.39 – 15.46SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.6M | −$9.6M | — | -0.05 | −$7.6M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$9.3M | −$8.4M | — | -0.05 | −$8.8M | — | — | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$8.3M | −$7.7M | — | -0.05 | −$4.9M | — | — | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$7.1M | −$6.8M | — | -0.06 | −$7.1M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$6.9M | −$6.6M | — | -0.07 | −$7.3M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$6.1M | −$5.8M | — | -0.07 | −$9.1M | — | — | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.9M | −$6.7M | — | -0.08 | −$7.2M | — | — | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$7.3M | −$7.1M | — | -0.10 | −$7.8M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$7.6M | −$7.5M | — | -0.13 | −$9.7M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$9.6M | −$9.6M | — | -0.21 | −$10.8M | — | — | May 13 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$8.2M | −$8.1M | — | -0.25 | −$4.8M | — | — | Mar 20 |
| Q3 2023 · Sep 30 | $0 | — | — | −$9.4M | −$9.3M | — | -0.33 | −$6.9M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$28.3M | −$26.9M | — | -0.25 | −$28.4M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$31.5M | −$30.9M | — | -0.50 | −$35.4M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$37.9M | −$37.3M | — | -1.34 | −$31.4M | — | — | — | — |
| FY2022 · to Dec 31 | $1M | 90.0% | −$42M | −$41.3M | -4130.1% | -2.13 | −$23.8M | — | — | — | — |
| FY2021 · to Dec 31 | $7.6M | 97.4% | −$25.3M | −$20.7M | -272.4% | -1.34 | −$26M | — | — | — | — |
| FY2020 · to Dec 31 | $1.9M | 100.0% | −$17M | −$16.8M | -881.9% | -2.11 | −$10.4M | — | — | — | — |
Every number comes from SELLAS Life Sciences Group, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.